The investigators plan to carry out an experimental study on the preventive effect of recombinant human interferon alpha nasal drops on the infection of 2019 new coronavirus in medical staff.
The investigators plan to carry out an experimental study enrolling more than 2000 medical staff and divide participants into low-risk group and high-risk group according to whether they can directly exposed to 2019-nCOV infected patients. In the low-risk group, participants will be given recombinant human interferon alpha-1b nasal drops (2-3 drops/nostril/ time, 4 times/ day), and in the high-risk group will be given preventive intervention with interferon nasal drops and thymosin-α (thymosin was injected subcutaneously once / week), and the intervention time is 28 days.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
2,944
recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.
thymosin alpha 1 subcutaneous injection 1 time per week.
Taihe Hospital
Shiyan, Hubei, China
RECRUITINGnew-onset COVID-19
new-onset coronavirus disease-2019
Time frame: From date of randomization until the diagnosis of COVID-19, assessed up to 6 weeks.
Number of Participants with coronavirus related symptoms
new-onset fever or respiratory symptoms but with negative pulmonary images evidence.
Time frame: during 28-day intervention.
Number of Participants with adverse effect
adverse effect of interferon α
Time frame: during 28-day intervention.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.